Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 2:35 pm Purchase |
2024-12-31 | 13G | Applied Therapeutics, Inc. APLT |
Vestal Point Capital, LP | 11,500,000 9.900% |
10,355,000 (+904.37%) |
Filing History |
| 2025-02-14 2:34 pm Sale |
2024-12-31 | 13G | uniQure N.V. QURE |
Vestal Point Capital, LP | 3,025,000 6.200% |
-1,725,000 (-36.32%) |
Filing History |
| 2025-02-14 2:33 pm Purchase |
2024-12-31 | 13G | Savara Inc. SVRA |
Vestal Point Capital, LP | 10,775,000 6.300% |
10,775,000 (New Position) |
Filing History |
| 2025-02-14 2:31 pm Purchase |
2024-12-31 | 13G | Nyxoah S.A. NYXH |
Vestal Point Capital, LP | 2,924,216 7.800% |
2,924,216 (New Position) |
Filing History |
| 2025-02-14 2:30 pm Purchase |
2024-12-31 | 13G | Immatics N.V. IMTX |
Vestal Point Capital, LP | 6,275,000 5.300% |
6,275,000 (New Position) |
Filing History |
| 2024-11-14 12:03 pm Purchase |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
Vestal Point Capital, LP | 4,000,000 7.100% |
4,000,000 (New Position) |
Filing History |
| 2024-11-14 12:03 pm Purchase |
2024-09-30 | 13G | Passage Bio, Inc. PASG |
Vestal Point Capital, LP | 6,100,000 9.900% |
6,100,000 (New Position) |
Filing History |
| 2024-11-14 12:02 pm Purchase |
2024-09-30 | 13G | Solid Biosciences Inc. SLDB |
Vestal Point Capital, LP | 2,800,000 7.300% |
2,800,000 (New Position) |
Filing History |
| 2024-11-14 12:02 pm Purchase |
2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Vestal Point Capital, LP | 4,000,000 9.300% |
4,000,000 (New Position) |
Filing History |
| 2024-11-14 12:02 pm Purchase |
2024-09-30 | 13G | Black Diamond Therapeutics, Inc. BDTX |
Vestal Point Capital, LP | 5,028,500 8.900% |
5,028,500 (New Position) |
Filing History |
| 2024-11-14 12:01 pm Purchase |
2024-09-30 | 13G | uniQure N.V. QURE |
Vestal Point Capital, LP | 4,750,000 9.800% |
825,000 (+21.02%) |
Filing History |
| 2024-11-14 12:00 pm Sale |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Vestal Point Capital, LP | 0 0.000% |
-3,000,000 (Position Closed) |
Filing History |
| 2024-11-14 12:00 pm Sale |
2024-09-30 | 13G | Applied Therapeutics, Inc. APLT |
Vestal Point Capital, LP | 1,145,000 1.000% |
-3,010,000 (-72.44%) |
Filing History |
| 2024-02-13 4:34 pm Purchase |
2023-12-31 | 13G | Applied Therapeutics, Inc. APLT |
Vestal Point Capital, LP | 4,155,000 5.400% |
4,155,000 (New Position) |
Filing History |
| 2024-02-13 4:34 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Vestal Point Capital, LP | 3,000,000 5.700% |
3,000,000 (New Position) |
Filing History |
| 2024-02-13 4:33 pm Purchase |
2023-12-31 | 13G | uniQure N.V. QURE |
Vestal Point Capital, LP | 3,925,000 8.200% |
3,925,000 (New Position) |
Filing History |